🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

212 results for “Bristol-Myers” Clear

  1. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  2. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Not the same excipients as Test, Balinatunfib

    Sanofi Pharma Bristol-Myers Squibb

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  4. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  7. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  8. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  9. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  10. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb / Pfizer EEIG

    Pan tumor

    phase 2 small molecule active

    1 trial

  11. PEGENZILEUKIN, Isatuximab, Isatuximab

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  12. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  14. PROMETHAZINE , DIPHENHYDRAMINE , CETIRIZINE , DEXCHLORPHENIRAMINE , PARACETAMOL , SAR443579

    Sanofi Pharma Bristol-Myers Squibb

    Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasia

    phase 2 small molecule active

    1 trial

  15. Placebo for bms-986435-01

    Bristol-Myers Squibb / Pfizer EEIG

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  16. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  17. Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Warm autoimmune hemolytic anemia

    phase 2 small molecule active

    1 trial

  18. Rilzabrutinib, Rilzabrutinib

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 2 small molecule active

    1 trial

  19. SAR421869

    Sanofi Pharma Bristol-Myers Squibb

    Usher's syndrome

    phase 2 small molecule active

    1 trial

  20. SAR422459

    Sanofi Pharma Bristol-Myers Squibb

    Congenital, hereditary and neonatal diseases

    phase 2 small molecule active

    1 trial

  21. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi Pharma Bristol-Myers Squibb

    Cancer

    phase 2 small molecule active

    1 trial

  22. SAR442970, NANOBODY® Placebo

    Sanofi Pharma Bristol-Myers Squibb

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  23. SAR443765 / LUNSEKIMIG

    Sanofi Pharma Bristol-Myers Squibb

    Chronic rhinosinusitis with nasal polyps

    phase 2 small molecule active

    1 trial

  24. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources